192 related articles for article (PubMed ID: 29395351)
1. End-Stage Renal Disease and Mortality Outcomes Across Different Glomerulonephropathies in a Large Diverse US Population.
Sim JJ; Bhandari SK; Batech M; Hever A; Harrison TN; Shu YH; Kujubu DA; Jonelis TY; Kanter MH; Jacobsen SJ
Mayo Clin Proc; 2018 Feb; 93(2):167-178. PubMed ID: 29395351
[TBL] [Abstract][Full Text] [Related]
2. Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population.
Sim JJ; Batech M; Hever A; Harrison TN; Avelar T; Kanter MH; Jacobsen SJ
Am J Kidney Dis; 2016 Oct; 68(4):533-544. PubMed ID: 27138468
[TBL] [Abstract][Full Text] [Related]
3. Patient characteristics and outcomes by GN subtype in ESRD.
O'Shaughnessy MM; Montez-Rath ME; Lafayette RA; Winkelmayer WC
Clin J Am Soc Nephrol; 2015 Jul; 10(7):1170-8. PubMed ID: 26092830
[TBL] [Abstract][Full Text] [Related]
4. Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA.
O'Shaughnessy MM; Montez-Rath ME; Lafayette RA; Winkelmayer WC
Nephrol Dial Transplant; 2016 Feb; 31(2):290-8. PubMed ID: 26610594
[TBL] [Abstract][Full Text] [Related]
5. Primary glomerulonephritis: an update on renal survival and determinants of progression.
Moranne O; Watier L; Rossert J; Stengel B;
QJM; 2008 Mar; 101(3):215-24. PubMed ID: 18245806
[TBL] [Abstract][Full Text] [Related]
6. Focal segmental glomerulosclerosis, excluding atypical lesion, is a predictor of renal outcome in patients with membranous nephropathy: a retrospective analysis of 716 cases.
He HG; Wu CQ; Ye K; Zeng C; Huang YY; Luo SW; Yin W; Ye QR; Peng XM
BMC Nephrol; 2019 Aug; 20(1):328. PubMed ID: 31438882
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in patients with biopsy-proved diabetic nephropathy compared to isolated lupus or crescentic glomerulonephritis.
Chou YH; Lin WC; Chen YM
Diabetes Res Clin Pract; 2019 Feb; 148():144-151. PubMed ID: 30641169
[TBL] [Abstract][Full Text] [Related]
8. Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry.
Norby GE; Mjøen G; Bjørneklett R; Vikse BE; Holdaas H; Svarstad E; Aasarød K
Lupus; 2017 Jul; 26(8):881-885. PubMed ID: 28059018
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and predictors for ESRD and mortality in primary GN.
Chou YH; Lien YC; Hu FC; Lin WC; Kao CC; Lai CF; Chiang WC; Lin SL; Tsai TJ; Wu KD; Chen YM
Clin J Am Soc Nephrol; 2012 Sep; 7(9):1401-8. PubMed ID: 22798538
[TBL] [Abstract][Full Text] [Related]
10. Change in novel filtration markers and risk of ESRD.
Rebholz CM; Grams ME; Matsushita K; Selvin E; Coresh J
Am J Kidney Dis; 2015 Jul; 66(1):47-54. PubMed ID: 25542414
[TBL] [Abstract][Full Text] [Related]
11. Cancer development and mortality differences in patients with glomerulonephritis after renal biopsy: a single center retrospective cohort study.
Ryu H; Kim K; Ryu J; Son HE; Ryu JY; Kim S; Na KY; Chae DW; Chin HJ;
BMC Nephrol; 2020 Jun; 21(1):221. PubMed ID: 32522167
[TBL] [Abstract][Full Text] [Related]
12. Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus Nephritis.
Gómez-Puerta JA; Feldman CH; Alarcón GS; Guan H; Winkelmayer WC; Costenbader KH
Arthritis Care Res (Hoboken); 2015 Oct; 67(10):1453-62. PubMed ID: 25624071
[TBL] [Abstract][Full Text] [Related]
13. Estimated glomerular filtration rate variability and risk of end-stage renal disease among patients with Stage 3 chronic kidney disease.
Perkins RM; Kirchner HL; Hartle JE; Bucaloiu ID
Clin Nephrol; 2013 Oct; 80(4):256-62. PubMed ID: 23993165
[TBL] [Abstract][Full Text] [Related]
14. Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies.
Mariani LH; Martini S; Barisoni L; Canetta PA; Troost JP; Hodgin JB; Palmer M; Rosenberg AZ; Lemley KV; Chien HP; Zee J; Smith A; Appel GB; Trachtman H; Hewitt SM; Kretzler M; Bagnasco SM
Nephrol Dial Transplant; 2018 Feb; 33(2):310-318. PubMed ID: 28339906
[TBL] [Abstract][Full Text] [Related]
15. Pattern of glomerular disease in the Saudi population: a single-center, five-year retrospective study.
Nawaz Z; Mushtaq F; Mousa D; Rehman E; Sulaiman M; Aslam N; Khawaja N
Saudi J Kidney Dis Transpl; 2013 Nov; 24(6):1265-70. PubMed ID: 24231502
[TBL] [Abstract][Full Text] [Related]
16. The spectrum of biopsy-proven glomerular diseases in a tertiary Hospital in Southern Brazil.
Thomé GG; Bianchini T; Bringhenti RN; Schaefer PG; Barros EJG; Veronese FV
BMC Nephrol; 2021 Dec; 22(1):414. PubMed ID: 34903188
[TBL] [Abstract][Full Text] [Related]
17. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.
Tanaka S; Ninomiya T; Katafuchi R; Masutani K; Nagata M; Tsuchimoto A; Hirakata H; Kitazono T; Tsuruya K
Clin Exp Nephrol; 2016 Oct; 20(5):689-698. PubMed ID: 26564155
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic predictors of death and ESRD in patients with pauci-immune necrotizing glomerulonephritis.
Kapitsinou PP; Ioannidis JP; Boletis JN; Sotsiou F; Nakopoulou L; Daphnis E; Moutsopoulos HM
Am J Kidney Dis; 2003 Jan; 41(1):29-37. PubMed ID: 12500219
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes for primary glomerulonephritis: New Zealand Glomerulonephritis Study.
Chembo CL; Marshall MR; Williams LC; Walker RJ; Lynn KL; Irvine J; Pilmore HL
Nephrology (Carlton); 2015 Dec; 20(12):899-907. PubMed ID: 26096749
[TBL] [Abstract][Full Text] [Related]
20. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
Pham PT; Pham PC
Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
